Prospective, randomized, controlled phase II clinical study of LDRT+SBRT to reverse resistance to first-line PD(L)-1 monoclonal antibody combination therapy in driver-negative stage IV non-small cell lung cancer

Hubei cancer hospital

Non-small cell lung cancer

Therapy Study

A Phase I clinical study to evaluate the safety and feasibility of αPD-L1/4-1BB modification with targeted DLL3 CAR-T cells in patients with relapsed or refractory small cell lung cancer (SCLC)

West China Hospital, Sichuan University

Extensive-stage Small Cell Lung Cancer

Therapy Study

Premarket

A single-center, single-arm, phase II prospective study to evaluate the efficacy and safety of PD-L1 inhibitors in the treatment of advanced non-small-cell lung carcinoma resistant or intolerant to PD-1 inhibitors

advanced non-small-cell lung carcinoma

Therapy Study

Post-market

A prospective, multicenter, non-interventional, real-world study to characterize changes in molecular markers after three weeks of targeted therapy with oxitinib in Chinese patients with stage IV metastatic or recurrent non-squamous EGFR-positive NSCLC

non-small cell lung cancer

Cause Study

Post-market

Transareolar single-port thoracoscopic lung resection for non-small cell lung cancer

Yantai Yuhuangding Hospital

non-small cell lung cancer

Therapy Study

Premarket

Clinical study of albumin paclitaxel combined with intrathoracic bevacizumab and loplatin in second-line treatment of patients with non-squamous non-small cell lung cancer with pleural effusion

Non-squamous non-small cell lung cancer with pleural effusion

Therapy Study

Post-market

The feasibility study of targeted curative effect prediction and precise treatment based on ctDNA dynamic monitoring for advanced NSCLC patients with newly diagnosed driver gene positive

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

Therapy Study

Dynamic monitoring of ctDNA and prediction of immune efficacy in advanced NSCLC patients with wild-typewith late initial driver gene and feasibility study based on ctDNA level intervention

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

non-small cell lung cancer

Therapy Study

Post-market

Clinical significance of peripheral blood exosomal target protein expression in early screening and prognosis of patients with lung non-small cell carcinoma

Chibi Pufang Hospital

non-small cell lung cancer

Diagnostic Accuracy Test

Premarket

Predictive biomarker discovery and clinical trials of the efficacy and safety of tislelizumab combined with chemotherapy in non-small cell lung cancer

Sun Yat-sen University Cancer Center

non-small cell lung cancer

Therapy Study

Post-market